Arcus Biosciences Inc (NYSE: RCUS) on Tuesday, plunged -4.29% from the previous trading day, before settling in for the closing price of $9.09. Within the past 52 weeks, RCUS’s price has moved between $6.50 and $18.98.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
A company in the Healthcare sector has jumped its sales by 76.65% annually for the last half of the decade. The company achieved an average annual earnings per share of -45.08%. With a float of $63.79 million, this company’s outstanding shares have now reached $105.90 million.
In an organization with 627 employees, it is important to assess its efficiency. In terms of profitability, gross margin is 96.45%, operating margin of -309.22%, and the pretax margin is -277.3%.
Arcus Biosciences Inc (RCUS) Insider and Institutional Ownership
Observing investor behavior towards Biotechnology industry stocks is more important than anything else. The insider ownership of Arcus Biosciences Inc is 39.75%, while institutional ownership is 62.43%. The most recent insider transaction that took place on Feb 27 ’25, was worth 201,200. In this transaction Director of this company bought 20,000 shares at a rate of $10.06, taking the stock ownership to the 28,400 shares. Before that another transaction happened on Feb 27 ’25, when Company’s Chief Executive Officer bought 19,800 for $10.18, making the entire transaction worth $201,465. This insider now owns 2,554,160 shares in total.
Arcus Biosciences Inc (RCUS) Latest Financial update
According to the Wall Street analysts, stocks earnings will be around -45.08% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will plunge by -8.36% during the next five years compared to -10.20% drop over the previous five years of trading.
Arcus Biosciences Inc (NYSE: RCUS) Trading Performance Indicators
Arcus Biosciences Inc (RCUS) is currently performing well based on its current performance indicators. A quick ratio of 5.37 was reported for the most recent quarter. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 6.53.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -4.19, a number that is poised to hit -1.13 in the next quarter and is forecasted to reach -4.56 in one year’s time.
Technical Analysis of Arcus Biosciences Inc (RCUS)
Let’s dig in a bit further. During the last 5-days, its volume was 1.39 million. That was better than the volume of 1.09 million it reported in year-ago period. As of the previous 9 days, the stock’s Stochastic %D was 16.08%. Additionally, its Average True Range was 0.61.
During the past 100 days, Arcus Biosciences Inc’s (RCUS) raw stochastic average was set at 30.14%, which indicates a significant increase from 7.04% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 73.50% in the past 14 days, which was higher than the 71.42% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $8.64, while its 200-day Moving Average is $12.82. However, in the short run, Arcus Biosciences Inc’s stock first resistance to watch stands at $9.02. Second resistance stands at $9.35. The third major resistance level sits at $9.51. If the price goes on to break the first support level at $8.53, it is likely to go to the next support level at $8.37. The third support level lies at $8.04 if the price breaches the second support level.
Arcus Biosciences Inc (NYSE: RCUS) Key Stats
Market capitalization of the company is 921.20 million based on 105,885K outstanding shares. Right now, sales total 258,000 K and income totals -283,000 K. The company made 28,000 K in profit during its latest quarter, and -112,000 K in sales during its previous quarter.
